Keywords Cytology-screening, statistics-epidemiological surveys.
|
|
- Junior Wilcox
- 5 years ago
- Views:
Transcription
1 DOI: /j x Epidemiology An examination of the role of opportunistic smear taking in the NHS cervical screening programme using data from the CSEU cervical screening cohort study RG Blanks, SM Moss, DA Coleman, AJ Swerdlow Cancer Screening Evaluation Unit, Institute of Cancer Research, Sutton, Surrey, UK Correspondence: Dr RG Blanks, Cancer Screening Evaluation Unit, Sir Richard Doll Building, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK. Accepted 19 June Published OnlineEarly 5 September Objective The objective of this study was to study the prevalence of opportunistic smear taking in the NHS cervical screening programme between 1999 and 2003 and the relationship of this to screening interval policy. Design A cohort study of nearly 2millionwomen,with data on screening at ages years from 1988 to 2003 has been constructed. Data from 1999 to 2003 have been used in this analysis. Screening episodes have been divided into those where the primary smear was initiated by the national call/recall system (invitational), normally at3-or5-yearlyintervals,and those initiated by the GP or woman (opportunistic). Opportunistic smears were further classified as routine (occurring within 6 months of 3 or 5 years) or sporadic (occurring at other times). Setting NHS cervical screening programme. Population Four Health Authorities in England (now Primary Care Trusts) with supplementary studies on national data. Methods Screening episodes have been defined. All episodes start with a primary smear defined as being invitational or opportunistic in origin. Main outcome measure Proportion of primary smear that were invitational or opportunistic. Results In total, 72% of incident screen primary smears were invitational and 28% were opportunistic. The proportion of opportunistic primary smears was 17 and 43% in 3- or 5-yearly screening policy areas, respectively, resulting in a considerably reduced average screening interval for women aged years in 5-year policy areas. Conclusion The NHS cervical screening programme is strongly influenced by opportunistic smear taking. In particular, nominally 5-year policy areas experienced much higher levels of opportunistic smear taking than those with a 3-year policy, causing the average interval in the 5-year areas to be much shorter than the policy would suggest. In future, with the change in national policy for inviting women aged years every 3 years and those aged years every 5 years, the level of opportunistic smear taking, particularly in the older group of women, needs to be carefully monitored. A lack of compliance may result in greater than predicted costs with little or no additional cancer prevention. Keywords Cytology-screening, statistics-epidemiological surveys. Please cite this paper as: Blanks R, Moss S, Coleman D, Swerdlow A. An examination of the role of opportunistic smear taking in the NHS cervical screening programme using data from the CSEU cervical screening cohort study. BJOG 2007;114: Introduction Background Cervical screening started in the UK in the mid-1960s. Although many women were having regular smear tests by the mid-1980s, there was concern that those at greatest risk were often not being tested and that not all those who had positive results were being followed up and treated effectively. As a result, the NHS cervical screening programme was set up in 1988 when the Department of Health instructed all Health Authorities to introduce computerised call/recall systems and to meet certain quality standards. The NHS call/recall system (the Exeter system ) invites women who have registered with a GP for screening and also keeps track of any follow-up investigation and when appropriate recalls women for screening at 3- or 5-year 1408 ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology
2 Opportunistic smears in NHS cervical screening intervals. Until 2003, the programme invited women between the ages of 20 and 64 years to be screened at a routine interval of either 3 or 5 years, depending on the Health Authority (now Primary Care Trust [PCT]) policy, but as a result of evidence from the UK programme, 1 the policy has changed to 3-yearly screening between the ages of 25 and 49 years and 5-yearly screening between the ages of 50 and 64 years. National screening programmes can be categorised as being organised (invitational) or opportunistic. Opportunistic smears are smears taken outside a call/recall invitation system and initiated by the woman herself or by her GP. A complexity of the UK programme is the role of these opportunistic smears taking place within an invitational screening programme, and as a result, the UK and some other national programmes have been called partially invitational. 2 High levels of opportunistic smear taking could reduce the average screening interval in practice compared with the local policy. We are undertaking a large cohort study to investigate further the effects of different screening intervals, the need for screening beyond the age of 50 years in women with a history of negative smears and the role of opportunistic smear taking. This paper outlines the design and construction of the cohort and presents initial results relating to the role of opportunistic smear taking. Methods Construction of cohort Study data were collected from four Health Authorities (now PCTs) in England. Two had a policy of 5-yearly screens, and two had a policy of 3-yearly screening. The population characteristics of the Health Authorities were broadly similar (Table 1) so that differences in outcome measures are most likely to reflect screening policy rather than population differences. The four Health Authorities agreeing to take part Table 1. Characteristics of Health Authorities included in the study cohort (2000/01 data) ONS area classification 1999 Townsend deprivation score* Interval policy ESI** formed two pairs of adjacent Health Authorities in different parts of England, one with a 3-year policy and one with a 5-year policy. Data from 1999 showed that approximately half of all Health Authorities in England had a 3-year policy and half a 5-yearly (or mixed 3 and 5 year) policy. We obtained a download of the records of all women who had been invited to screening from each of the four Health Authorities since the start of computerisation of records. The final cohort contains records of women screened between 1 January 1988 and 31 December In this paper, the present analysis has been restricted to smears taken between 1 January 1999 and 31 December 2003 inclusive because of problems with data quality and variations in coding between regions in the data before 1999 and also to get the best and most current estimates of opportunistic smear taking. Definitions To analyse the extent of opportunistic screening, it is necessary to define several parameters to differentiate types of smear within the study dataset. To obtain a consistent and pragmatic analysis, we have recognised the episodic nature of smear taking, and the analyses are based around smears that initiate new screening episodes rather than including all individual smears within an episode. Episodes and primary or secondary smears We have defined an episode as a series of smears starting with a primary smear that is initiated either by the call/recall system or by the GP or by the woman herself and ending with a closing smear that results in the woman being returned to routine recall (Figure 1). Any subsequent smears carried out as a consequence of the primary smear are termed secondary smears. When a woman has a nonnegative smear result, she may end up being referred to colposcopy (and suspended in the call/recall system). The smear that results in a referral to colposcopy is defined as the referral smear, and the woman may be treated and undergo a further series of smears before the episode is closed by a negative smear returning her to routine recall. The time between the primary smear and the closing smear is the length of the episode, and most episodes (where the primary smear is negative) are therefore of length Somerset Rural Berkshire Prosperous Dorset Coast and Services Oxfordshire Prosperous Primary smear Referral smear Closing smear ONS, Office for National Statistics. *Negative scores are more affluent, and positive scores are more deprived. **Estimated using 2000/01 KC53 returns. Additional secondary smears Figure 1. An example of a screening episode indicating primary, referral and closing smears. For most women, the primary smear will be negative and will therefore also be the closing smear. ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology 1409
3 Blanks et al. zero because the primary smear is also the closing smear. For some women, an episode can last for many years. Episodes can be further divided into prevalent screen episodes (a woman s first smear episode) and incident screen episodes (a subsequent smear episode). In this paper, we use only those incident episodes where a woman has a previous episode in the cohort database, for which the interval since the closing smear of the previous episode (the screening interval) can therefore be calculated. For a minority of women, the grouping of smears into episodes can be difficult either due to nonattendance for repeat smears or due to conflicting data for two smears; detailed rules [obtainable from the cancer screening evaluation unit (CSEU)] were therefore established to allow all smears to be considered as part of an episode. Primary smears as invitational or opportunistic Primary smears can be considered invitational where the woman is invited by the call/recall system (known as the Exeter system) itself or opportunistic where the smear is initiated by a GP or by the woman herself and not as the result of a system invitation. For a small proportion of primary smears, insufficient information exists to classify the primary smear, and these primary smears are classed as undefined. An episode can therefore also be defined as invitational or opportunistic depending on the origin of its primary smear. Opportunistic primary smears can be further divided into routine and sporadic. A routine opportunistic primary smear is defined as one taken at a normal routine interval; between 2.5 and 3.5 years for a 3-year policy area or between 2.5 and 3.5 years or 4.5 and 5.5 years for a 5-year policy area. Routine opportunistic smears will be used to measure routine 3-yearly screening occurring in 5-year policy areas. Opportunistic primary smears taken outside these intervals are defined as sporadic. A glossary of terms is included in the Appendix. Supplementary studies Data from the 2000/01 annual Health Authority returns to the Department of Health (KC53 returns) were used to check whether the screening interval in practice for the four Health Authorities was in line with the stated policy (Table 1) and to provide additional information for all of the 99 Health Authorities in England. The screening interval can be crudely estimated by dividing the proportion of women screened within the past 3 years by the proportion screened within the past 5 years (P). This ratio would be 0.6 if all women were rescreened at 5 years, and 1.0 if all women were rescreened at 3 years; an estimated screening interval (ESI) can therefore be estimated as 8 5P. This supplementary information has been used to determine how representative the four Health Authorities are of English Health Authorities overall and to help make inferences to all of England from the cohort. Results During 1 January 1999 to 31 December 2003, there were primary smears initiating incident screen episodes (originating from a total of women) of which (92%) were episodes where the primary smear could be categorised as invitational or opportunistic. There were undefined episodes (8%) where missing or contradictory information did not enable the episode to be thus categorised. Of the incident screen episodes, 87% were single smear episodes, where the primary smear was also the closing smear, and 13% were multi-smear episodes. In total, 25% of multi-smear episodes and 3.6% of all episodes included a referral smear resulting in the woman being referred to colposcopy. Of the categorised primary smears, (72%) were invitational and (28%) were opportunistic. Of the opportunistic smears, (44%) were routine opportunistic and (56%) were sporadic opportunistic. Table 2 shows the primary smears analysed by local interval policy and age. For all women (aged years), the invitational proportion was far higher in 3-year policy (83%) than in 5-year (57%) policy areas, with 17 and 43% of primary smears, respectively, being opportunistic. Invitational smears were marginally more common for older women than younger women regardless of policy. Routine opportunistic smears were particularly common in 5-year policy areas (21%) where they represent routine 3-yearly screening in a 5-yearly policy area. In 3-yearly areas, only Table 2. Number and percentage of incident screen primary smears by type, age group and interval policy Type of primary smear and age group at smear Three-year policy (%) Five-year policy (%) Within age group, Invitational years (71.3) 6768 (45.8) years (82.1) (55.3) years (87.7) (62.2) years (83.2) (56.6) Routine opportunistic years 1983 (9.5) 3294 (22.3) years (6.0) (21.2) years 5275 (4.6) (20.6) years (5.8) (21.1) Sporadic opportunistic years 4004 (19.2) 4721 (31.9) years (11.9) (23.4) years 8745 (7.7) (17.2) years (11.0) (22.3) 1410 ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology
4 Opportunistic smears in NHS cervical screening 6% of smears were classified as routine opportunistic. Sporadic opportunistic smears were more common in 5-year policy (22%) than in 3-year policy areas (11%) and also in younger women irrespective of policy. Figure 2A, B show the percentage of incident episode primary smears that were invitational or opportunistic for 3- and 5-year policy areas. Routine opportunistic smears in 3-year policy areas tended to occur mostly between 30 and 36 months and probably represent opportunistic smear taking in women due to an invitation in the near future, perhaps because the GP felt that they might not attend the invitation or because it was more convenient to do the smear there and then. Figure 2A shows that sporadic opportunistic smear taking in 3-yearly policy areas mostly relates to women screened between 24 and 30 months, with a small additional peak at 48 months, the latter presumably being smears taken in women who did not attend their 3-yearly invitation. In 5-yearly policy areas, where 21% of smears were sporadic, these occurred mostly between 42 and 54 months, representing early screening in a 5-yearly policy area. (Figure 2B). Overall, in 5-yearly areas, 84.7% of opportunistic smears occurred at less than 54 months (which could be considered A Percentage of primary smears B Percentage of primary smears Screening interval (months) Screening interval (months) Figure 2. Percentage of incident screen primary episodes that are invitational (solid line) or opportunistic smears (dotted line) by screening interval (time since previous closing smear) for all areas over for women aged years by (A) 3-year policy areas and by (B) 5-year policy areas. an early screen) compared with 3-yearly areas where only 43.1% of opportunistic smears were taken at less than 30 months. Details of percentages of opportunistic smears occurring in 3- and 5-yearly areas by age group and interval are given in Table 3, and for all smears, the details are given in Table 4. For brevity, these tables only include age groups and years, which are the age groups currently invited to screening following recent policy changes. Opportunistic smears that are not early may be smears taken at a more convenient time just before an invitation was due or a smear taken after an invitation when the woman was a nonresponder. Overall, 9.4% of all primary smears in women aged years in 3-yearly areas were early, increasing to 50.6% in 5-year areas. For women aged years, these figures were 5.4 and 38.1%, respectively. External validity of cohort results We investigated whether the above results can be applied to the whole of England. In the four Health Authorities included in the cohort using data from the 2000/01 annual returns, the ESI ranged from 4.66 in Somerset, which has a 5-year policy, to 3.60 in Dorset with a 3-year policy. Berkshire had a higher proportion of opportunistic smears than Somerset and also had a shorter ESI of 4.33 versus 4.66 (Table 1). Overall, for all 99 Health Authorities in 2000/01, the ESI varied from 3.56 to 4.82 with a mean of Those Health Authorities with 3-year policies had a mean ESI of 3.76 (range ), while those with a 5-year policy had a mean of 4.41 (range ). Figure 3 shows the percentage of all smears taken opportunistically as reported in the annual returns against the ESI in 2000/01 from all Health Authorities with a 5-year screening policy. Increased use of opportunistic smear taking is associated with decreasing screening interval. Only one Health Table 3. Number of opportunistic smears (percentage) occurring within specified time periods in 3- and 5-year policy areas for age groups and years Policy Interval (months) Ages years, Ages years, 3 year (43.5)* 5579 (39.8)* (33.5)** 5275 (37.6)** (12.5) 1705 (12.2) (4.1) 487 (3.5) (6.3) 974 (6.9) 5 year (24.8)* 5960 (20.5)* (35.5)* (40.5)* (24.4)* 6338 (21.8)* (12.0)** 4094 (14.1)** (3.3) 936 (3.2) *Early. **Correct interval. ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology 1411
5 Blanks et al Estimated Screening interval % opportunistic Fitted line Authority (Avon (ESI = 4.82) has evidence of a true 5-year interval in practice, as well as policy; the mean ESI in Figure 3 is 4.41, suggesting that opportunistic smear taking results in an average screening interval less than the 5-year policy. We estimate that the level of opportunistic smear taking in all 5-year policy areas is around 50%, rather than the 43% from our two areas combined in the cohort study and that Berkshire is more representative of the average 5-year policy area than Somerset. Our results may therefore be marginally conservative when applied to the whole of England. Discussion Berkshire Somerset Figure 3. Percentage of smears that are opportunistic versus ESI for Health Authorities in England with a 5-year screening policy (data from 2000/01 annual returns). A number of studies have examined the effectiveness of organised versus opportunistic smear taking 3,4 but have not come to consistent conclusions. Miller 5 has argued that when Table 4. Number of all smears (percentage) occurring within specified time periods in 3- and 5-year policy areas for age groups and years Policy Interval (months) Ages years, Ages years, 3 year (9.4)* 6174 (5.4)* (66.7)** (77.6)** (15.1) (10.6) (3.7) 2981 (2.6) (5.1) 4259 (3.8) 5 year (13.2)* 6494 (8.4)* (23.9)* (20.4)* (13.5)* 7113 (9.2)* (40.5)** (54.9)** (8.9) 5412 (7.0) *Early. **Correct interval. invasive cancer is used as an endpoint, organised screening is more effective because opportunistic smears tend to be taken frequently in young women and have less impact on invasive cancer incidence. The use of opportunistic smear taking in England is in some ways different because of the use until recently of a dual screening policy where women could be invited at 3- or 5-yearly intervals. The NHS cervical screening programme is strongly influenced by opportunistic smear taking. In the extreme, one Health Authority with a 5-yearly policy actually had an ESI shorter than another Health Authority with a 3-yearly policy. Clearly, screening interval policy and practice may be very different as a result of opportunistic smear taking. With the recent change in screening programme policy in England (such that all women aged years will, in future, be invited every 3 years and women aged years every 5 years), careful monitoring will be required. The new policy will require GPs in the previous 3-year policy areas to screen women aged years at a longer, 5-year, interval. If, as we have shown, many GPs in the previous 5-yearly policy areas screen women aged years opportunistically at shorter intervals than 5 years, then GPs in the previous 3-year policies areas may be reluctant to adopt the new policy of screening at 5-yearly intervals for this age range. Hence, opportunistic smear taking could result in a national programme with screening intervals in practice that are markedly different to policy. Screening women aged years, 3-yearly, is likely to result in higher costs with little gain in additional cancer protection. 1 In our cohort, 31% of smears in women aged years in 5-yearly screening areas were early opportunistic smears occurring more than 6 months before the recommended screening interval; this is similar to the percentage (at all ages) of negative smears found to be interval smears in a study in Bristol, 6 which concluded that discouraging such smears could reduce laboratory workload by 30%. The routine measurement of the ESI for women aged and years from PCT returns (KC53 returns) may be a simple method of tracking screening interval, and hence the likely use of opportunistic smears, as the national programme changes to the new screening policy. In the future, improvements could be made to the information available from standard returns to enable a more precise measure of screening interval to be developed. Conclusions These results suggest that GPs (and women) often do not adhere to a local 5-year policy and in practice may screen women much earlier. The effect is that the real screening interval is much less between 3- and 5-year policy areas than would be anticipated and that opportunistic smears may limit the effect of the new English policy of 5-yearly screening at ages years ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology
6 Opportunistic smears in NHS cervical screening Contribution to authorship R.G.B. helped design the study, analyse the data and write the paper. S.M.M. helped design the study and write the paper. D.A.C. helped design the study and analyse the data. A.J.S. helped design the study and write the paper. Acknowledgements We thank Aida Sanchez for her work in the data management of the cohort and to the Health Authorities for supplying the data. The Cancer Screening Evaluation Unit receives funding from the Department of Health Policy Research Programme; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive or Department of Health. The study has Patient Information Advisory Group (PIAG) approval and was deemed by the Multi-Centre Research Ethics Committee (MREC) not to require their approval, as it did not include the collection of any other data that was already routinely collected. The study is funded by the Department of Health. j References 1 Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89: Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91: Gustafsson L, Sparen P, Gustafsson M, Wilander E, Bergstrom R, Adami HO. Efficiency of organised and opportunistic cytological screening for cancer in situ of the cervix. Br J Cancer 1995;72: Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999;83: Miller AB. The (in)efficiency of cervical screening in Europe. Eur J Cancer 2002;38: Channer JL, Mackenzie EF. A study of the effect of introducing a restrictive cervical screening policy on laboratory workload and cervical cancer detection rates. Cytopathology 1990;1: Appendix Glossary Primary smear Referral smear Closing smear Episode Prevalent episode Incident episode Exeter (call/recall) primary smear Opportunistic primary smear/episode Routine opportunistic smear/episode Sporadic opportunistic smear/episode The first smear in an episode The smear that leads a woman being referred to colposcopy The last smear in an episode. A primary smear which is negative will also be the closing smear. Closing smears are always negative A single primary smear or a sequence of smears initiated by the primary smear that ends with a closing smear, which is a negative smear test that returns the woman back to routine recall A woman s first episode A subsequent screening episode An episode started by a primary smear, which has resulted from the woman being invited to be screened by the national call/recall system An episode started by a primary smear that resulted from a decision to do a smear test from the GP or the woman but not initiated by the call/recall system An episode started by an opportunistic smear taken at a standard interval between 2.5 and 3.5 years or between 4.5 and 5.5 years, usually the former. These smears are mostly the result of GPs undertaking 3-yearly screening in a 5-year policy area* An episode started by an opportunistic smear taken between 0 and 2.5 years, 3.5 and 4.4 years or more than 5.5 years after a previous closing smear and not initiated by the national call/recall system *Note that the small number of prevalent screen opportunistic smears would be considered routine opportunistic. ª 2007 The Authors Journal compilation ª RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology 1413
Northern Ireland Cervical Screening Programme
Northern Ireland Cervical Screening Programme ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 1 Report produced by : Quality Assurance Reference Centre, PHA Date of Publication: September 2012 2 Contents
More informationCERVICAL SCREENING WALES CERVICAL SCREENING PROGRAMME, WALES: 2001/02
CERVICAL SCREENING WALES INFORMATION TEAM STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2001/02 For more information about this report contact: Helen Beer, Information Analyst / Manager, Screening
More informationKC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales
KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales CERVICAL SCREENING WALES STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2012/2013 For more information
More informationCervical cytology or the molecular model: which is the best way forward?
Cervical cytology or the molecular model: which is the best way forward? Pekka Nieminen, M.D. Chief Physician, Associate Professor Dept. of Obstetrics & Gynaecology Helsinki University Central Hospital
More informationComparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer
BJOG: an International Journal of Obstetrics and Gynaecology August 2004, Vol. 111, pp. 842 848 DOI: 1 0. 1111/j.1471-0528.2004.00210.x Comparison of HPV test versus conventional and automation-assisted
More informationNHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology
NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express
More informationCervical Screening. Bexley Bromley and Greenwich (BBG) Annual Report 2009/10. Dr Angela Bhan Screening Commissioner
Cervical Screening Bexley Bromley and Greenwich (BBG) Annual Report 2009/10 Dr Angela Bhan Screening Commissioner 1 Contents EXECUTIVE SUMMARY 3 1. NHS Cervical Screening Programme 1.1 Local programme
More informationScreen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening
DOI: 10.1111/j.1471-0528.2008.01989.x www.blackwellpublishing.com/bjog Epidemiology Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening
More informationScreening for Cervical Cancer in Europe
Asturias, 23 October, 2011 Asturias, 23 October Screening for Cervical Cancer in Europe M. Arbyn Unit Cancer Epidemiology, IPH, Brussels, Belgium Rue Juliette Wytsmanstraat 14 1050 Brussels Belgium T +32
More informationThe new European (and Italian) guidelines for cervical screening will recommend PAP from 25 to 34 HPV (+ triage) from 35 to 64
The new European (and Italian) guidelines for cervical screening will recommend PAP from 25 to 34 HPV (+ triage) from 35 to 64 risk of overdiagnosis and over treatment Failures in reproductive functioning:
More informationKing s Research Portal
King s Research Portal DOI: 10.1111/cyt.12259 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA):
More informationCERVICAL SCREENING WALES
CERVICAL SCREENING WALES Cervical Screening Wales Audit of Cervical Cancer (CSWACC) National Report 1999-2009 For more information about this report contact: Dr Rose Fox Director Cervical Screening Wales
More informationPOLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS
POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS Reference Number Version: Status Author: Alison Cropper CL-CP/2009/010 V3 Final Job Title: Hospital Based Programme
More informationPreventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE
Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE DR GARY FENTIMAN, CLINICAL LEADER COLPOSCOPY, N C S P TAKE-HOME LESSONS Vaccination is Primary Prevention for Cervical Cancer Women
More informationPrimary High Risk HPV Testing with Cytology Triage
Primary High Risk HPV Testing with Cytology Triage NHS Cervical Screening Programme Public Health England leads the NHS Screening Programmes Human papillomavirus (HPV) High risk (HR) HPV is associated
More informationNorthern Ireland cervical screening programme. Information for primary care and smear takers
Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25
More informationHow invasive cervical cancer audit affects clinical practice
How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust How invasive
More informationThe introduction of HPV testing to cervical screening in Scotland
The introduction of HPV testing to cervical screening in Scotland Frequently asked questions for professionals Key messages From early 2020, cervical cytology (looking at cells under a microscope) will
More informationQuestions and answers paper
Questions and answers paper From Monday, June 6 th 2016*, the age range for cervical screening will change from ages 20 60 years, to ages 25 64 years plus 364 days. The frequency of cervical screening
More informationEUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF ESTONIA
EUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF EUROCHIP-2 ACTION IN ESTONIA Impact of implementing a nationwide cervical cancer screening programme on population coverage by Pap-tests and on proportion
More informationNHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT
Kingston Borough Team Richmond and Twickenham Borough Team 1. Introduction NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT 2010-12 All women between the ages of 25 and 64 are eligible
More informationANNEX 07 - LATVIA MEDIA GUIDE on CERVICAL CANCER IN LATVIA
European Commission Directorate C Public Health and Risk Assessment Health & Consumer Protection Directorate general GRANT AGREEMENT n 2007121 EUROCHIP-III European Cancer Health Indicator Project-III
More informationNational Diabetes Audit
National Diabetes Audit Executive Summary Key findings about the quality of care for people with diabetes in England and Wales Report for the audit period 2007-2008 Prepared in partnership with: Executive
More informationWaiting Times for Suspected and Diagnosed Cancer Patients
Waiting Times for Suspected and Diagnosed Cancer Patients 2015-16 Annual Report Waiting Times for Suspected and Diagnosed Cancer Patients 1 Waiting Times for Suspected and Diagnosed Cancer Patients Prepared
More information07 August Dear Colleague,
07 August 2018 Dear Colleague, Further to our letter dated 9 May 2018, we are writing today to all healthcare professionals registered with CervicalCheck with updated advice and information regarding CervicalCheck.
More informationNATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017
a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor
More informationUK National Screening Committee HPV as primary screen for cervical cancer - an evidence review. Consultation comments pro-forma.
UK National Screening Committee HPV as primary screen for cervical cancer - an evidence review Consultation comments pro-forma Name: Sarah May Email address: sarahmay@ibms.org Organisation (if appropriate):
More information6 th EFC Satellite meeting, Saturday 1 st December 2018
6 th EFC Satellite meeting, Saturday 1 st December 2018 Introduction Pekka Nieminen President-elect of the European Federation for Colposcopy, Department of Obstetrics and Gynaecology, Helsinki University
More informationNORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN
Improving Your Health and Wellbeing NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN 211-212 QUALITY ASSURANCE REFERENCE CENTRE August 213 1 2 Contents Page Summary 4 Introduction
More informationCELLULAR PATHOLOGY DEPARTMENT STANDARD OPERATING PROCEDURE INSTRUCTIONS FOR CERVICAL CYTOLOGY SAMPLE TAKERS
Implementation date: October 2006 Page 1 of 7 CELLULAR PATHOLOGY DEPARTMENT STANDARD OPERATING PROCEDURE INSTRUCTIONS FOR CERVICAL CYTOLOGY SAMPLE TAKERS Purpose: This procedure has been written to provide
More informationNational Surveillance System for Human Papillomavirus Infection and Related Disease in Scotland
National Surveillance System for Human Papillomavirus Infection and Related Disease in Scotland Version Date: 10th October 2008 Proposal prepared by: M O Leary (EPIET), C. Robertson (Statistics), K. Sinka
More informationDear Colleagues, EXTENSION OF PAUSE TO THE USE OF VAGINAL MESH
29/03/2019 NHS Improvement and NHS England Wellington House 133-155 Waterloo Road London SE1 8UG 020 3747 0000 www.england.nhs.uk www.improvement.nhs.uk To: Regional Directors, Trust Medical Directors,
More informationScottish Cervical Screening Programme. Colposcopy and Programme Management
Scottish Cervical Screening Programme Colposcopy and Programme Management Addendum to NHSCSP Publication No 20 Second Edition Exceptions Applicable in NHS Scotland April 2013 (Final Version 2.8 to incorporate
More information7.14 Young Person and Adult (YPA) Screening Programmes
7. ADULT SECTION 7.14 Young Person and Adult (YPA) Screening Programmes Screening is a process of identifying apparently healthy people who are at increased risk of a disease or condition, to offer information,
More informationInterval Cancers in BreastScreen Aotearoa
Interval Cancers in BreastScreen Aotearoa 2008 2009 Released 2018 nsu.govt.nz Citation: National Screening Unit. 2018. Interval Cancers in BreastScreen Aotearoa 2008 2009. Wellington: Ministry of Health.
More informationNHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT
NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT 2009-2012 NHSCSP audit of invasive cervical cancer: national report 2009-2012 i Lead Authors Professor Peter Sasieni Professor of Biostatistics
More informationNHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.
NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report. Sue Moss, Christopher Mathews Centre for Cancer Prevention, Wolfson Institute, Queen Mary University
More informationZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust
ZedScan Case Study NHS Hospital, UK. ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust Increased detection
More informationPublic Health Agency NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN QUALITY ASSURANCE REFERENCE CENTRE
Public Health Agency Improving Your Health and Wellbeing NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 QUALITY ASSURANCE REFERENCE CENTRE August 2012 1 2 Contents
More information2. CANCER AND CANCER SCREENING
2. CANCER AND CANCER SCREENING INTRODUCTION The incidence of cancer and premature mortality from cancer are higher in Islington compared to the rest of England. Although death rates are reducing, this
More informationPublished text: Institute of Cancer Research Repository Please direct all s to:
This is an author produced version of an article that appears in: CYTOPATHOLOGY The internet address for this paper is: https://publications.icr.ac.uk/9928/ The definitive version is available at: www3.interscience.wiley.com
More informationSE Coast Cervical Screening QARC Interim Guidance for laboratories on cervical sample acceptance
SE Coast Cervical ing QARC Interim Guidance for laboratories on cervical sample acceptance List of accepted reasons/categories for sample rejection and inadequate cytology reports in SE Coast Version 6,
More informationEffect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years
DOI: 10.1111/j.1471-0528.2008.01853.x www.blackwellpublishing.com/bjog Gynaecological oncology Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50
More informationWORKING TOGETHER FOR THE NHS 20/07/2018
20/07/2018 NHS Improvement and NHS England Wellington House 133-155 Waterloo Road London SE1 8UG 020 3747 0000 www.england.nhs.uk www.improvement.nhs.uk To: Regional Directors, Trust Medical Directors,
More informationBoard Meeting Tuesday 17 August 2004 Board Paper No. 04/52 PUBLIC HEALTH ISSUE - GGNHSB CERVICAL SCREENING PROGRAMME - ANNUAL REPORT 2002/2003
EMBARGOED UNTIL MEETING Greater Glasgow NHS Board Board Meeting Tuesday 17 August 2004 Board Paper No. 04/52 DIRECTOR OF PUBLIC HEALTH PUBLIC HEALTH ISSUE - GGNHSB CERVICAL SCREENING PROGRAMME - ANNUAL
More informationDraft Breast Screening Health Equity Audit Lambeth PCT
Draft Breast Screening Health Equity Audit Lambeth PCT 11.02.2003-26.01.2006 Table of Contents Backg...3 Figure 1: Breast cancer registrations by year and age group in Lambeth...3 The most recent local
More informationGOVERNING BODY MEETING IN VITRO FERTILISATION (IVF) AND ASSISTED CONCEPTION CONSULTATION. Matt Rangué, Chief Nurse, NHS Southend CCG
AGENDA ITEM 5. GOVERNING BODY MEETING IN VITRO FERTILISATION (IVF) AND ASSISTED CONCEPTION CONSULTATION Date of the meeting 1 st February 2018 Author Sponsoring Governing Body Member Purpose of Report
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Smith M, Lew JB, Simms K, Canfell K. Impact of HPV sample self-collection
More informationAscertaining and reporting interval cancers in BreastScreen Aotearoa: A protocol NATIONAL SCREENING UNIT (NSU) MINISTRY OF HEALTH
Ascertaining and reporting interval cancers in BreastScreen Aotearoa: A protocol NATIONAL SCREENING UNIT (NSU) MINISTRY OF HEALTH Dr. Simon Baker National Screening Unit Ministry of Health October 2005
More information14. Cancer of the Cervix Uteri
KEY FACTS 14. Cancer of the Cervix Uteri ICD-9 180 On average 78 cases of invasive cervical cancer were registered per year. Half of cases occurred under 49 years of age. 2% of female cancers. Higher than
More informationHow to combine screening and vaccination How to promote women s health and prevent cancer with good screening strategies
How to combine screening and vaccination How to promote women s health and prevent cancer with good screening strategies Pekka Nieminen, M.D. Chief Physician, Associate Professor Dept.Obstetrics & Gynaecology
More informationThe routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy
The routine use of ZedScan within one colposcopy service in England MC Macdonald, R Lyon, JE Palmer, JA Tidy Introduction Colposcopic impression alone has been shown to be subjective with variable rates
More informationTrust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme
Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More informationClosing the Data Gap. Louise Galloway Senior Advisor, Population Health Policy and Programs. Department of Health & Human Services
Closing the Data Gap Louise Galloway Senior Advisor, Population Health Policy and Programs Renewal: It is not just about changing the test 1. Improving data 2. Improving participation 3. They are interlinked
More informationCancer in the South West Peninsula - a baseline assessment
Cancer in the South West Peninsula - a baseline assessment 1 The Cancer Reform Strategy 1.1 The Cancer Reform Strategy, published in December 2007 1, built on the progress already achieved since the publication
More informationCOLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY. Dorota Gertig, Marion Saville
COLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY Dorota Gertig, Marion Saville on behalf of the C QuIP Steering Committee June 2013 1 CONTENTS 1. Executive
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationThese comments are an attempt to summarise the discussions at the manuscript meeting. They are not an exact transcript.
Dear dr. Weber, We would like to thank you for the review of our manuscript entitled Cervical screening with an interval beyond five years requires different rescreen times for HPV-negative and HPVpositive,
More informationT his article is based on a recent report from
62 EFFECTIVENESS BULLETIN A systematic review of cancer waiting time audits R Lewis, R Collins, A Flynn, M Emmans Dean, L Myers, P Wilson, A Eastwood... A summary of a systematic review of clinical audits
More informationActivity Report March 2013 February 2014
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland
More informationNational Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns
National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns Routes to Diagnosis: Investigation of melanoma unknowns About Public Health England Public Health England exists
More informationLocally Enhanced Service for Stopping Smoking
NHS Devon Locally Enhanced Service for Stopping Smoking This Local Enhanced Service (LES) Specification details the agreement between Devon PCT (the commissioner) and community pharmacies (the service
More informationCERVICAL SCREENING. a pocket guide. Cancer Screening Programmes
CERVICAL SCREENING a pocket guide Cancer Screening Programmes CERVICAL SCREENING a pocket guide This booklet is a simple guide to cervical screening. We hope you find it useful whether you work for or
More informationNational Bowel Cancer Audit Supplementary Report 2011
National Bowel Cancer Audit Supplementary Report 2011 This Supplementary Report contains data from the 2009/2010 reporting period which covers patients in England with a diagnosis date from 1 August 2009
More informationDetermining the cost-effectiveness of mass screening for cervical cancer using common analytic models Sato S, Matunaga G, Tsuji I, Yajima A, Sasaki H
Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models Sato S, Matunaga G, Tsuji I, Yajima A, Sasaki H Record Status This is a critical abstract of an economic
More informationHealth Audit. Norfolk Public Health Improving health and wellbeing Protecting the population Preventing ill health.
Norfolk Public Health Improving health and wellbeing Protecting the population Preventing ill health Health Audit By: Dr Kadhim Alabady, Principal Epidemiologist Dr Shamsher Diu, Public Health Consultant
More informationCervical screening. Cytology-based screening programmes
HPV-FASTER: broadening the scope for prevention of HPV-related cancer Combining the complementary approaches of HPV vaccination and screening could accelerate declines in the burden of cervical cancer
More informationGDm-Health is free to download and use. Its use may result in efficiency savings from reducing face-to-face clinic appointments.
pat hways Health app: GDm-Health for people with gestational diabetes Medtech innovation briefing Published: 13 November 2017 nice.org.uk/guidance/mib131 Summary About this app GDm-Health is a health application
More informationCuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015
Programme Report 2014/2015 Contents Summary points 2 Introduction to the statistics 2014/2015 3 Part 1 Cervical screening activity 3 Programme coverage 4 Laboratory turnaround time 7 Notification of results
More informationEuropean Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs
European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs Introduction to the Survey The purpose of this project is to collect information regarding
More informationSMALL DESIGN SMART INNOVATION
SMALL DESIGN SMART INNOVATION The new Touch and Ultra Changing the Face of Colposcopy Significant improvements have changed the cervical cancer screening pathway over the last 20 years, resulting in high
More informationTitle:The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines
Author's response to reviews Title:The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines Andrzej Nowakowski (andrzejmnowakowski@poczta.onet.pl)
More informationQA and Quality Indicators for Cervical Cancer Screening Programs. Guglielmo Ronco MD Senior Epidemiologist CPO Piemonte Turin, Italy
QA and Quality Indicators for Cervical Cancer Screening Programs Guglielmo Ronco MD Senior Epidemiologist CPO Piemonte Turin, Italy Disclosures No financial relationships or conflict of interest to disclose
More informationPathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading
DOI: 10.1111/j.1471-0528.2006.01207.x www.blackwellpublishing.com/bjog Gynaecological oncology Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading P Priest,
More informationThe Control of Cervical Cancer in New Zealand: Achievements and Prospects
The Control of Cervical Cancer in New Zealand: Achievements and Prospects August 5 th 2016, Potter s Park Event centre, Auckland Purpose of the Symposium The purpose of the one day forum, organised by
More informationCOUNCIL RECOMMENDATION of 2 December 2003 on cancer screening (2003/878/EC)
L 327/34 COUNCIL RECOMMDATION of 2 December 2003 on cancer screening (2003/878/EC) THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, and in particular
More informationNational Cancer Peer Review Programme. Radiotherapy Service Evidence Guide
National Cancer Peer Review Programme Radiotherapy Service Evidence Guide Forward This evidence guide has been formulated to assist organisations in preparing for peer review. The contents of this guide
More informationBritain against Cancer APPG Cancer Meeting 2009 Research & Technologies Workshop
Britain against Cancer APPG Cancer Meeting 2009 Research & Technologies Workshop Researching inequality and cancer - what we know and what requires further research David Forman, Michael Chapman, Jon Shelton
More informationTARGETS To reduce the age-standardised mortality rate from cervical cancer in all New Zealand women to 3.5 per or less by the year 2005.
Cervical Cancer Key points Annually, around 85 women die from, and 230 women are registered with, cervical cancer. The decline in both incidence and mortality rates for cervical cancer has accelerated
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More informationINTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)
INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT NECN N Tees & Hartlepool North Tees And Hartlepool Date Self Assessment Completed 23rd July 2009 Date of IV Review 19th June 2009
More informationEstimating the efficacy of screening by auditing smear histories of women
Bridsh Journal of Cancer (1996) 73, 1001-1005 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 M Estimating the efficacy of screening by auditing smear histories of women with and without cervical
More informationImplementation of High Risk Human Papilloma Virus (Hr-HPV) Primary Testing
Implementation of High Risk Human Papilloma Virus (Hr-HPV) Primary Testing Background In Nov 2015 following a review of evidence the UK National Screening Committee made a recommendation to the UK countries
More informationGuideline for the Follow-up of Patients with Gynaecological Malignancies
Guideline for the Follow-up of Patients with Gynaecological Malignancies Version History Version Date Summary of Change/Process 2.0 20.02.08 Endorsed by the Governance Committee 2.1 18.11.10 Circulated
More informationScreening for Chronic Disease. Prof. A. Miller
Screening for Chronic Disease Prof. A. Miller Non-communicable diseases (NCD) Comprise: Cardiovascular diseases Cerebrovascular diseases Cancer Chronic respiratory diseases Diabetes Non-communicable diseases
More informationBreastScreen Victoria Annual Statistical Report
BreastScreen Victoria Annual Statistical Report 005 Produced by: BreastScreen Victoria Coordination Unit Level, Pelham Street, Carlton South Victoria 05 PH 0 9660 6888 FX 0 966 88 EM info@breastscreen.org.au
More informationProgramme Report Irish Cervical Screening Programme. October 2000 to August 2008
Programme Report Irish Cervical Screening Programme October 2000 to August 2008 Members of the Board of the National Cancer Screening Service Dr Sheelah Ryan, Chairperson Dr Gráinne Flannelly Dr Marie
More informationHaringey. CCG Governing Body. Immunisation and Screening Update. Report. May 2015
1 Haringey CCG Governing Body Immunisation and Screening Update Report May 2015 Aim of the report This report is an update for the Haringey CCG Governing Body on the section 7a Immunisation and Screening
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationInvestigation into the management of health screening
A picture of the National Audit Office logo Report by the Comptroller and Auditor General Department of Health & Social Care Investigation into the management of health screening HC 1871 SESSION 2017 2019
More informationRandomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years
British Journal of Cancer (2005) 92, 949 954 All rights reserved 0007 0920/05 $30.00 www.bjcancer.com Randomised controlled trial of mammographic screening in women from age 40: results of screening in
More informationPsychological Therapies, Annual Report on the use of IAPT services: England 2013/14 EXPERIMENTAL STATISTICS
Psychological Therapies, Annual Report on the use of IAPT services: England 2013/14 EXPERIMENTAL STATISTICS Published 17 September 2014 We are the trusted national provider of high-quality information,
More informationExperience of the Finnish mass screening system
British Journal of Preventive and Social Medicine, 1977, 31, 238-244 Selective screening for cervical cancer Experience of the Finnish mass screening system MATTI HAKAMA AND EERO PUKKALA From the Finnish
More informationEfficacy of cervical intrarepithelial neoplasia (CIN)
The Ulster Medical Journal, Volume 72, No. 1, pp. 10-15, May 2003. Efficacy of cervical intrarepithelial neoplasia (CIN) treatment by cold coagulation A Zawislak, J H Price, H R McClelland, R G N Storey,
More informationSouth East Coast Operational Delivery Network. Critical Care Rehabilitation
South East Coast Operational Delivery Networks Hosted by Medway Foundation Trust South East Coast Operational Delivery Network Background Critical Care Rehabilitation The optimisation of recovery from
More informationThe role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial
DOI: 10.1111/j.1471-0528.2010.02519.x www.bjog.org Epidemiology The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial
More informationUniversity of Birmingham and University of York Health Economics Consortium (NCCID) Development feedback report on piloted indicators
University of Birmingham and University of York Health Economics Consortium (NCCID) Development feedback report on piloted indicators QOF indicator area: Gestational diabetes Pilot period: 1 st October
More informationEffectiveness of opportunistic screening for cancer of the cervix uteri
Original Article Effectiveness of opportunistic screening for cancer of the cervix uteri Roderick Busuttil, Miriam Dalmas, Albert Cilia Vincenti Abstract The incidence and mortality of uterine cervical
More informationIntegrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014
Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 31 March KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative
More informationWHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE
WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE EXECUTIVE SUMMARY Incidence of cancer is rising, with one in two people born after 1960 expected to be diagnosed
More information